About Us

Company Overview

Advancing therapies to give people the power to restore their health and transform their lives

Kailera is an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive, and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.

With significant experience developing and commercializing therapies for metabolic diseases, Kailera’s leadership team is positioned to efficiently and effectively advance our pipeline. Within this large, growing disease area, we remain committed to identifying and delivering on future opportunities to better serve people living with obesity.

“Obesity has become one of the most pressing health challenges of our time. While the approvals of GLP-1-based obesity management medications have changed the landscape of obesity management, there remains a critical need for medications offering greater weight loss, especially for those living with a higher BMI. Our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.”

Ron Renaud

President & Chief Executive Officer

With our obesity-first focus, we have built a diversified pipeline of product candidates specifically designed to address critical needs in the current therapeutic landscape. Our lead product candidate, ribupatide (also known as KAI-9531), is a once-weekly injectable GLP-1/GIP receptor dual agonist peptide currently being evaluated in a global Phase 3 program that builds on the compelling results of the clinical program to date.

We are also advancing three additional clinical programs, which include our lead dual agonist ribupatide formulated as a once-daily oral tablet, KAI-7535, an oral small molecule GLP-1 receptor agonist and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. These programs are designed to address the vastly diverse additional unmet needs of those living with obesity or overweight.

Kailera’s pipeline was in-licensed through a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a leading global pharmaceutical company with robust research and development capabilities. We hold exclusive rights to the development and commercialization of our product candidates outside of China, Hong Kong, Macau and Taiwan. Hengrui’s clinical trials of our product candidates in China provide us with access to a broad and deep clinical data set that informs and accelerates our global development plans.